Anatomic Pathology Market Size ,Share & Trends Analysis Report By Application (Disease Diagnosis, Drug Discovery & Development), By Product & Services (Instruments, Consumables), By End Use, And Segment Forecasts, 2019 - 2025

Industry Insights

The global anatomic pathology market size was estimated at USD 15.4 billion in 2018 and is expected to register a CAGR of 6.1% over the forecast period. Increase in clinical use of biomarkers enables pathologists to determine disease pathogenesis at a molecular level and guides in clinical decision-making, thereby improving patient outcomes. Growing reliance on biomarkers-based pathology tests and procedures to explore common malignancy and tumorigenesis is driving the market.

High usage of advanced pathology equipment such as staining systems, gross imaging, and digital microscopes is poised to improve anatomic pathological practices to a major extent. Digital imaging solutions offer specificity and accuracy-related benefits over conventional techniques, which in turn, boosts the service uptake rate in the overall market.

Companies are undertaking continuous efforts for the development of advanced and upgraded pathology equipment with respect to their design and ease of use. Moreover, there have been several partnership and agreement ventures among key companies for the introduction of an effective portfolio in order to circumvent challenges pertaining to disease management.

For instance, in October 2018, Sakura Finetek USA partnered with Laboratory Medicine and Henry Ford Health System Pathology to advance the automation level of its anatomic pathology laboratories. The incorporation of automation in labs optimizes anatomical pathology workflows by minimizing errors and turnaround time, and also offers high productivity.

The significant number of pathology-training programs by government authorities aim to increase awareness about technological and legal issues prevalent in anatomic pathology. These training modules also emphasize on the theoretical knowledge of trainees, consequently addressing the market challenge of the dearth of skilled professionals.

Product & Services Insights

A substantial number of reagents and kits, antibodies, and probes are being marketed for anatomic pathology protocols. Some key reagents and kits are Tamping Tools Kits, CISH Centromere Detection Kits by Thermo Fisher, ultraView SISH DNP Detection Kit, ISH iVIEW Blue Plus Detection Kit by Roche, and Instrument Cleaning Kit by Agilent.

Availability of a wide range of products, coupled with high usage rate of consumables in research findings, is responsible for the major share of the segment in terms of revenue generation. On the other hand, ongoing technological advancements and focused efforts by market participants to offer anatomic pathological instruments with an improved design is anticipated to bolster revenue growth through the instruments segment.

In September 2018, Sakura Finetek introduced the manual microtome Accu-Cut SRM 300 LT. This product was integrated with 4-color LED-backlit 3D Precision Chuck, a new feature that enables observing paraffin-embedded tissue samples in a more simplified manner for rapid visualization of translucent biopsies.

Application Insights

Anatomical pathology protocols provide an opportunity for researchers to explore disease etiology and associated outcomes. Thus, wide application in disease diagnosis accounted for the largest revenue share in the anatomic pathology market in 2018.

This workflow aids the detection of a tumor at inflammatory and proliferating stromal cells stage, thus minimizing costs associated with tumor eradication. In addition, increasing focus of manufacturers on introduction of innovative and novel diagnostics techniques accelerates segment growth.

Drug discovery and development is anticipated to grow at a lucrative pace over the forecast period. Tissue analysis carried out by pathologists generates a wealth of information for pharmaceutical manufacturers during preclinical trials. Anatomic pathology plays a vital role in toxicology assessment, for the evaluation of the adverse effects of candidate drugs.

End-use Insights

Hospitals dominated the market with respect to revenue in 2018 owing to high hospitalization rate of cancer patients, coupled with a substantial number of frequent readmissions in hospitals. Moreover, presence of well-developed infrastructure as well as well-trained staff in hospital-based pathological laboratories stimulates the progression of the hospital segment.The segment is also expected to benefit from increasing number of initiatives undertaken by public and private agencies to promote advanced healthcare systems.

The emergence of advanced testing techniques and equipment has led to lucrative growth opportunities in the diagnostic laboratories segment. Similarly, a large number of clinical trials through various ongoing projects has spurred the progression of the research laboratories segment. Research laboratories are engaged in offering rapid and comprehensive information about the functioning of diseased tissues, with an overall objective of achieving a high degree of patient satisfaction.

Regional Insights

North America accounted for the largest revenue share in 2018 due to the presence of major players and supportive government initiatives pertaining to training pathological programs. Rising implementation of tissue-diagnostic related procedures in disease screening owing to favorable reimbursement policies in U.S. facilitates regional market growth.

Spiraling demand for advanced imaging modalities, increase in better patient care facilities, and several pathology laboratories franchising their presence fuels the Asia Pacific market. Presence of public agencies, such as Pathology Branch of the Chinese Medical Association in China aimed at assisting pathology projects, also contribute to regional growth.

Anatomic Pathology Market Share Insights

Prominent participants operating in this market include Thermo Fisher Scientific, Inc.; Cardinal Health, Inc.; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Sakura Finetek USA, Inc.; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; NeoGenomics Laboratories, Inc.; BioGenex; and Bio SB.

These key players are implementing multiple strategies to maintain their significant share in the marketplace during the forecast period. The strategies implemented include collaborative development, business expansion, and product developments.

For instance, in June 2018, Agilent Technologies introduced a range of probes, such as MALT1, BCL2, CCND1, MYC, BCL6, IGH, IGH/MYC, IGH/BCL2, and IGH/CCND1, for in situ hybridization. Launch of these products enhanced the company’s portfolio, thus strengthening its position in the sector.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global anatomic pathology market report on the basis of product & service, application, end use, and region:

• Product & Services Outlook (Revenue, USD Million, 2014 - 2025)

  • Instruments

    • Microtomes & Cryostat

    • Tissue processors

    • Automatic Stainers

    • Other products

  • Consumables

    • Reagents & Antibodies

    • Probes & Kits

    • Others

  • Services

• Application Outlook (Revenue, USD Million, 2014 - 2025)

  • Disease Diagnosis

  • Drug Discovery and Development

  • Others

• End-use Outlook (Revenue, USD Million, 2014 - 2025)

  • Hospitals

  • Research Laboratories

  • Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • Middle East and Africa (MEA)

    • South Africa